Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01656174 · ClinicalTrials.gov registry record
Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross
A clinical trial of Dengue, sponsored by Gen-Probe, Incorporated.
- Completed
- Registry status
- 35,035
- Enrollment target
- 2
- Study locations
NCT01656174 is a study of Dengue that has completed, run by Gen-Probe, Incorporated. The registered enrollment target is 35,035 participants, above the 88-participant average among 9 other Dengue trials with a reported enrollment target (39713% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT01656174, a study of Dengue, has completed, sponsored by Gen-Probe, Incorporated.
- COMPLETED
- Registry status
- 35,035 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this study is to test individual donor samples (IDSs) with the investigational Dengue Assay on the TIGRIS System and to further characterize the Dengue Assay in the clinical setting.
Conditions Studied
Interventions
- DEVICE Procleix Dengue Virus Assay
Study Locations (2)
Arizona
- Creative Testing Solutions - Tempe
North Carolina
- American Red Cross National Testing Laboratory - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35,035 participants |
| Start Date | 2012-08 |
| Est. Completion | 2015-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01656174
The ClinicalTrials.gov registry entry for NCT01656174 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 35,035 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 88-participant average among 9 other Dengue trials with a reported enrollment target (39713% higher). The listed sponsor is Gen-Probe, Incorporated, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dengue appearing as the primary indexed condition, and to 1 intervention - of which Procleix Dengue Virus Assay is the first listed.
NCT01656174 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01656174 about?
NCT01656174 is a clinical study titled "Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross". The objective of this study is to test individual donor samples (IDSs) with the investigational Dengue Assay on the TIGRIS System and to further characterize the Dengue Assay in the clinical setting.
What is the current status of trial NCT01656174?
This trial is currently completed. The enrollment target is 35,035 participants. The study started on 2012-08. Estimated completion is 2015-01.
What conditions does trial NCT01656174 study?
This clinical trial studies the following conditions: Dengue.
What interventions are being tested in trial NCT01656174?
The interventions under investigation include: Procleix Dengue Virus Assay (DEVICE).
Who is sponsoring clinical trial NCT01656174?
This trial is sponsored by Gen-Probe, Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01656174 being conducted?
This trial has 2 study locations across Arizona, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dengue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults
COMPLETED · Phase 1
-
TDENV PIV and LAV Dengue Prime-boost Strategy
COMPLETED · Phase 1
-
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
COMPLETED · Phase 1
-
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults
COMPLETED · Phase 1
-
ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
COMPLETED · Phase 1
-
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.